Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter’s Specialized Hospital, Addis Ababa, Ethiopia

Table 2

Clinical characteristics of MDR-TB patients in SPSH, 2020 (n = 484).

Variables		Frequency	Percent (%)
Methods of diagnosis	Gene Xpert	359	74.2
	Culture	72	14.9
	Line probe assay	46	9.5
	Clinically suspected	7	1.4
Type of MDR-TB	Pulmonary TB	389	80.4
	Extra-pulmonary TB	95	19.6
Initial sputum smear result (n = 389)	Positive	87	22.4
	Negative	302	77.6
Previous treatment for TB	Yes	329	68.0
	No	155	32.0
Baseline weight	<43 kg	172	35.5
	≥43 kg	312	64.5
	Median (IQR)	45.5 (40–52)	—
Substance use	Nonusers	363	75
	Alcohol	105	21.7
	Khat	14	2.9
	Khat and alcohol	1	0.2
	Smoker	1	0.2
Number of drug used for MDR-TB therapy	4	117	24.2
	5	363	75.0
	≥6	4	0.8
Initiation of MDR-TB medication	At the day of diagnosis	392	81.0
	Within 10 days of diagnosis	91	18.8
	After 30 days of diagnosis	1	0.2
Drug adverse effects	Yes	463	95.7
	No	21	4.3
Type of adverse effects (n = 463)	GI symptoms	332	68.6
	Peripheral neuropathy	139	28.7
	Hypothyroidism	25	5.2
	Ototoxicity	31	6.4
	Psychiatric symptoms	33	6.8
	Hypokalemia	118	24.4
	Drug-induced hepatitis	44	9.1
Clinical complication	Yes	96	19.8
	No	388	80.2
Type of complication	Pneumonia	59	61.5
	Hemoptysis	16	16.7
	Pneumothorax	13	13.5
	Arthritis	7	7.3
	Cor pulmonale	1	1.0
Presence of lung cavities (n = 389)	Yes	57	14.7
	No	332	85.3

IQR: interquartile range.